Amazon is developing a vaccine against the common cold: report

Amazon logo on the side of a building
Amazon is yet to publicly acknowledge the existence of the common cold research group. (Sundry Photography/Shutterstock)

Amazon is trying to develop a vaccine against the common cold, CNBC reports. The secretive project is part of an Amazon unit that, like Alphabet’s X, is trying to find solutions to big problems outside of the company’s traditional wheelhouse.

The sheer number of viruses that cause the common cold, coupled with the rate at which they mutate, has deterred many research groups from trying to find treatments or vaccines for the condition. To add to the challenge, the relatively benign, short-lived symptoms associated with the common cold mean a product will likely need a squeaky clean safety and tolerability profile to gain acceptance. 

Yet, with one analysis putting the annual cost of the common cold to the U.S. economy in lost productivity at $25 billion, there is potentially a significant opportunity for a company with a product that strikes the careful balance needed to succeed in the space. Amazon wants to be that company.

Sponsored by BHE

[Webinar] State of Data Analytics and Machine Learning in the Life Sciences Industry: 2020 Benchmarking Survey

Thursday, June 25, 2020 | 2:00pm ET | 11:00am PT

Join us Thursday, June 25th for a look at the current state of analytics in the life sciences industry. We will present the results from our industry survey with FiercePharma on how 100 of your peers are leveraging data analytics to respond to today’s challenges and generate timely, high value insights.

The Seattle-based e-commerce giant has reportedly tasked a small team at its 100-person Grand Challenge unit, the R&D division code-named 1492, with working on ways to tackle the common cold. Amazon is aiming to develop a vaccine against the common cold, but it is also exploring other ways of curbing the impact the condition has on society.

Exactly how Amazon is approaching the challenge, and how much money it is committing, remains unknown, with the company yet to publicly acknowledge the existence of Grand Challenge, let alone the common cold research group.

In recent years, researchers at groups other than Amazon have published papers about possible ways to treat and prevent the common cold. For example, in 2016 the authors of a paper in Nature Communications linked the administration of a polyvalent inactivated rhinovirus vaccine to the inducement of virus-neutralizing antibodies in monkeys. However, none of the projects has matured to the point that a vaccine against or treatment for the common cold is on the horizon. 

Suggested Articles

Singapore is planning to outfit each of its 5.7 million residents with a simple wearable device to track people who have been exposed to COVID-19.

The agency delivered its first batch of antibody test results in May, covering a dozen products independently evaluated by the NIH and CDC.

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.